There are currently 129 active clinical trials seeking participants for Multiple Sclerosis research studies. The states with the highest number of trials for Multiple Sclerosis participants are Florida, New York, California and Texas.
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722
Recruiting
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/09/2024
Locations: Novartis Investigative Site, Birmingham, Alabama +108 locations
Conditions: Multiple Sclerosis
Register for Updates
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
NCT05982925
Recruiting
In this protocol, a combination of MRI, blood, and cerebrospinal fluid (CSF) analysis will be used to understand the natural history, underlying immunologic mechanisms, and clinical implications of central nervous system (CNS) lesions, in particular lesions in the cerebral cortex, in multiple sclerosis (MS) and other inflammatory and autoimmune disorders affecting the CNS. Patients with these disorders, as well as healthy controls, will undergo baseline clinical evaluation and testing, bloodwork... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: Mount Sinai Hospital, New York, New York
Conditions: Multiple Sclerosis, Neuromyelitis Optica, Demyelinating Autoimmune Diseases, CNS
Register for Updates
Effectiveness of Task Specific Home Exercise Program
NCT06486116
Recruiting
The purpose of this study is to compare the effectiveness of 2 different types of Home Exercise Programs (HEP) on mobility in persons with Multiple Sclerosis (MS). Specifically, we will be comparing the Standard of Care (SOC) a program based on aerobic conditioning and calisthenics to a Task Specific Program (TSP). Primary Question: Will persons with who receive a Task Specific HEP have greater improvement in mobility than those who receive the SOC? Secondary question: Will a task specific HEP... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/26/2024
Locations: New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York
Conditions: Multiple Sclerosis
Register for Updates
Remote Evaluation of MIND Diet
NCT06450977
Recruiting
The goal of this clinical trial is to learn if increasing adherence to a Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet pattern improves thinking ability and memory compared to a healthy control diet in persons with Multiple Sclerosis (MS). The main question it aims to answer is: Does the MIND diet improve cognitive performance relative to a control diet in persons with MS? Participants will: Consume one meal that follows the MIND diet or a control meal every day for... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/25/2024
Locations: University of Illinois Urbana-Champaign, Urbana, Illinois
Conditions: Multiple Sclerosis, Cognitive Change, Nutrition, Healthy
Register for Updates
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
NCT05658497
Recruiting
The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks after the first day of their last menstrual period (LMP) up through the first trimester of pregnancy and to comparatively evaluate pregnancy outcomes with MCMs in women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the fir... Read More
Gender:
Female
Ages:
All
Trial Updated:
06/21/2024
Locations: IQVIA US Office, Durham, North Carolina +4 locations
Conditions: Multiple Sclerosis
Register for Updates
Multiple Sclerosis Falls Insight Track
NCT05837949
Recruiting
The purpose of this study is to develop an application: MS Falls Insight Track (MS FIT) which allows patients to log their falls and near falls, view their MS relevant data and responses to the clinic intake survey as well as communicate with their care team about falls and receive educational material on falls prevention.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Multiple Sclerosis
Register for Updates
Non-invasive BCI-controlled Assistive Devices
NCT05183152
Recruiting
Injuries affecting the central nervous system may disrupt the cortical pathways to muscles causing loss of motor control. Nevertheless, the brain still exhibits sensorimotor rhythms (SMRs) during movement intents or motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. Brain-computer interfaces (BCIs) can decode SMRs to control assistive devices and promote functional recovery. Despite rapid advancements in non-invasive BCI systems ba... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/06/2024
Locations: The University of Texas at Austin, Austin, Texas
Conditions: Motor Disorders, Healthy, Spinal Cord Injuries, Muscular Diseases, Motor Neuron Disease, Stroke, Traumatic Brain Injury, Movement Disorders, Multiple Sclerosis
Register for Updates
Ketamine for MS Fatigue
NCT06064162
Recruiting
The purpose of this study is to see whether using ketamine to increase glutamate in the prefrontal cortex can reduce Multiple Sclerosis (MS) related fatigue. The investigator proposes a prospective, crossover, randomized, placebo-controlled study to assess the efficacy and safety of low, single dose Ketamine, to assess its efficacy and safety in patients with MS-related fatigue.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/05/2024
Locations: Alta Bates Summit Medical Center, Berkeley, California
Conditions: Multiple Sclerosis
Register for Updates
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
NCT06170970
Recruiting
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that these agents may be beneficial specifically for MS patients with concomitant excessive daytime sleepiness. This study uses a randomized, double-blind, placebo-controlled crossover design. Participants will undergo a 10-day lead-in with he medicati... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/04/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Multiple Sclerosis, Multiple Sclerosis Fatigue
Register for Updates
High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis
NCT05735691
Recruiting
The goal of this clinical trial is to improve walking speed, balance, and walking in the community for people with multiple sclerosis. This trial involves intense exercise combined with walking on a shaky treadmill. Walking on a shaky treadmill helps to practice balance and intense exercise promotes the ability to walk faster and farther. In this study, participants will train with a combination of high or low intensity, and with a stable or shaky treadmill. Walking speed and endurance, balance... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2024
Locations: Rehabilitation Hospital of Indiana, Indianapolis, Indiana +1 locations
Conditions: Multiple Sclerosis
Register for Updates
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
NCT04002934
Recruiting
The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS). The investigators will utilize electrophysiologic techniques and magnetic resonance imaging to quantify the effect of treatment in 50 women over the course of 6 months. Participants may remain on their standard disease modifying treatment during the course of the trial but may not concurrently participate in any other investigatio... Read More
Gender:
Female
Ages:
Between 40 years and 65 years
Trial Updated:
05/29/2024
Locations: Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California
Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
NCT04933552
Recruiting
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
Gender:
Female
Ages:
All
Trial Updated:
05/14/2024
Locations: Novartis Investigative Site, La Jolla, California
Conditions: Multiple Sclerosis
Register for Updates